Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam/ß-lactamase inhibitor combination

Abstract

Objectives: Cefepime/tazobactam is a new ß-lactam/ß-lactamase inhibitor combination licensed for clinical use by Drugs Controller General of India. Aim of our study was to analyze the clinical efficacy and safety of cefepime/tazobactam in patients with sepsis. To the best of our knowledge, this is the first published clinical study on this drug. Materials and methods:A retrospective observational study on the efficacy and safety of cefepime/tazobactam was conducted at a tertiary care hospital, South India. Patients who had a clear source of infection, having a single organism as the causative agent and being treated with cefepime/tazobactam alone were analyzed for efficacy and those cases who had a clear source of infection but either had multiple organism grown or cultures being negative or those patients who received a combination of antibiotics were analyzed for the safety analysis.Results: Thirty two patients satisfied our study criteria. All 15 patients in the efficacy group (nine with ventilator associated pneumonia, three tracheitis, two bacteraemia and one with urosepsis) had complete clinical cure, with microbiological cure in cases where a repeat culture was indicated. There were no significant side effects in any of the evaluable 32 patients assessed for safety. Gereç ve yöntem:Sefepim/tazobaktam'ın etkinlik ve güvenilirliği üzerine Güney Hindistan'da üçüncü basamak bir bakım merkezinde retrospektif bir gözlem çalışması yapıldı. Enfeksiyon kaynağı belli olan, tek bir mikroorganizmanın etken olarak izole edildiği ve tek başına sefepim/tazobaktam ile tedavi edilen hastalar etkinlik açısından incelendi ve belirgin bir enfeksiyon kaynağı olduğu halde birden çok organizma üreyen veya kültürü negatif olan yada tedavi için bir antibiyotik kombinasyonu alan hastalar güvenilirlilik analizi için incelendi.

A Comparative In Vitro Sensitivity Study of “Ceftriaxone–Sulbactam–EDTA” and Various Antibiotics against Gram-negative Bacterial Isolates from Intensive Care Unit

“…Several reports suggest that B-lactam/B-lactamase inhibitors (BL/BLI) combinations like cefoperazone–sulbactam, piperacillin–tazobactam and ampicillin–sulbactam can be used as suitable options for treating less severe cases, 6 , 7 whereas carbapenems can be used as reserve drug for more severe cases.…”

Quantification and stress degradation studies of cefepime/tazobactam in dry injection form by an RP-HPLC method

“…TAZ is semi-synthetic parenteral penicillin. It is a β-lactamase inhibitor with a broad spectrum of antibacterial activity against most gram positive, gram negative aerobic and anaerobic bacteria (Ghafur, Ashwini, Priyadarshini, 2012.). Chemically, it is known as (2S,3S,5R)-3-methyl-7oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylic acid 4, 4-dioxide ( Figure 2).…”

Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care

“…Inadequate access to such novel MDR and active therapies in countries such as India and China, coupled with a significant compromise in the effectiveness of older BL-BLIs, has resulted in a crippling therapeutic void in the treatment of contemporary Gram-negative infections (9,(19)(20)(21)(22). Meanwhile, indigenous pharmaceutical firms in these countries resorted to marketing several unorthodox BL-BLI combinations, namely, ceftriaxone-tazobactam, ceftazidime-tazobactam, cefoperazone-tazobactam, cefepime-tazobactam, cefotaxime-sulbactam, ceftazidime-sulbactam, ceftriaxone-sulbactam, cefepime-sulbactam, and meropenemsulbactam (Table 1) (9,(23)(24)(25)(26)(27). The doses of the BLIs in all these combinations were retained at the same ratios used in the older scientifically developed combinations, such as piperacillin-tazobactam and ampicillin-sulbactam.…”